Janssen Announces European Commission Approval of JULUCA®▼ (dolute
Dolutegravir/rilpivirine, the result of a collaboration with ViiV Healthcare...
2018-05-22
文传商讯
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/ri
If approved, stable, virologically suppressed adults living with HIV-1 could...
2018-03-28
文传商讯
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA Shows Posi
Once-daily single tablet complete regimen demonstrates effective viral suppr...
2017-10-27
文传商讯
European Commission Approves Symtuza for the Treatment of HIV-1 In Adul
Symtuza is the only darunavir-based single-tablet regimen (STR) approved for...
2017-09-28
文传商讯
Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Com
- Interim results from the pivotal EMERALD trial presented during an oral se...
2017-07-26
文传商讯
Johnson & Johnson Announces Encouraging First-in-Human Clinical Data fo
In Phase 1/2a APPROACH study, HIV-1 antibody response observed in all health...
2017-07-25
文传商讯
